Glenmark Pharma creates a world record, in honor of India’s healthcare warriors: Glenmark Pharmaceuticals successfully achieved a world record for the largest pin badge sentence, ‘Pride of India’ on 18th of August 2021, in Mumbai.
A total of 22,373 Indian flag pin badges were used to create the sentence. Over 15,000 diabetologists, cardiologists and physicians from across the country participated and supported this unique initiative honouring our frontline warriors.
This achievement is aimed to honour our healthcare warriors, who have been on the frontlines of our nation’s battle against COVID-19, safeguarding our lives whilst risking theirs!
Glenmark Pharmaceuticals is a pioneer in the Diabetes Care segment in India. It is the first company in the world to launch its novel, patent protected and globally-researched sodium glucose co-transporter-2 (SGLT2) inhibitor Remogliflozin etabonate by the brand names REMOZEN and has launched multiple brand extensions like REMOZEN-M, REMOZEN V in the market.
The Company has also been at the forefront in the country’s fight against COVID-19 with its Favipiravir brand FabiFlu.
Know More About Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology.
It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). The company has been listed in the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the third consecutive year in a row.
DJSI is one of the world’s most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index. For more information, visit www.glenmarkpharma.com